Jänne PA - Search Results

1

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.

Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA. Cheng ML, et al. Among authors: janne pa. JCO Precis Oncol. 2022 Nov;6:e2200382. doi: 10.1200/PO.22.00382. JCO Precis Oncol. 2022. PMID: 36455195 No abstract available.

2

Lung cancer presenting with solitary bone metastases. Case 2: acrometastasis as an initial presentation of non-small-cell lung carcinoma.

Jänne PA, Datta MW, Johnson BE. Jänne PA, et al. J Clin Oncol. 1999 Sep;17(9):2998-3001. doi: 10.1200/JCO.1999.17.9.2998. J Clin Oncol. 1999. PMID: 10561378 No abstract available.

3

Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy.

Jänne PA, Rodriguez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE. Jänne PA, et al. Oncology. 2001;61(3):175-83. doi: 10.1159/000055371. Oncology. 2001. PMID: 11574771 Review.

4

Basic treatment considerations using chemotherapy for patients with small cell lung cancer.

Johnson BE, Jänne PA. Johnson BE, et al. Among authors: janne pa. Hematol Oncol Clin North Am. 2004 Apr;18(2):309-22. doi: 10.1016/j.hoc.2003.12.008. Hematol Oncol Clin North Am. 2004. PMID: 15094173 Review. No abstract available.

5

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: janne pa. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125

6

[Gefitinib therapy in non-small-cell lung cancer].

Jänne PA. Jänne PA. Duodecim. 2005;121(3):249-51. Duodecim. 2005. PMID: 15787283 Finnish. No abstract available.

7

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

Jänne PA, Engelman JA, Johnson BE. Jänne PA, et al. J Clin Oncol. 2005 May 10;23(14):3227-34. doi: 10.1200/JCO.2005.09.985. J Clin Oncol. 2005. PMID: 15886310 Review.

8

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Eberhard DA, et al. Among authors: janne pa. J Clin Oncol. 2005 Sep 1;23(25):5900-9. doi: 10.1200/JCO.2005.02.857. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043828 Clinical Trial.

9

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Mukohara T, et al. Among authors: janne pa. J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94. doi: 10.1093/jnci/dji238. J Natl Cancer Inst. 2005. PMID: 16106023

10

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

Johnson BE, Jänne PA. Johnson BE, et al. Among authors: janne pa. Cancer Res. 2005 Sep 1;65(17):7525-9. doi: 10.1158/0008-5472.CAN-05-1257. Cancer Res. 2005. PMID: 16140912 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

468 results

Search Page